Regulatory Roundup: FDA Announced Upcoming Part 11 Inspections; And More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Announced Upcoming Part 11 Inspections; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration announced last week that it will be “conducting a series of inspections in an effort to evaluate industry’s compliance and understanding of [21 CFR] Part 11.” The agency intends to take appropriate action to enforce Part 11 requirements for issues raised during the inspections that do not fall under the enforcement discretion discussed in the 2003 Guidance for Industry: Part 11, Electronic Records; Electronic Signatures—Scope and Application. (See related blog post.)

   
FDA also issued a new Guidance for Industry: Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions, Annex 13. This particular annex harmonizes the analytical procedures used for bulk density and tapped density of powders across the US, Europe, and Japan. ICH adopted Annex 13 in June 2010. FDA has published other harmonized Q4B annexes as guidance’s over the past year, including Annex 5 Disintegration Test, 7 Dissolution Test, 8 Sterility Test, 9 Tablet Friability, and 10 Polyacrylamide Gel Electrophoreses.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here